Cramer's 'Mad Money' Recap: Retreat to Defensive Stocks

Investing in Helium

Right now the money is in helium, and that means it's time to look at pulling the trigger on Air Products & Chemicals (APD Quote).

Last week, there was a story in The Wall Street Journal about a global helium shortage, Cramer said. Helium is found only in a few places, and one of the largest supplies is expected to run out in eight years, Cramer said.

One of Air Products' smaller competitors recently raised its prices, and now Air Products has the opportunity to do the same, Cramer said. The stock is a couple of points from its high, and right now is a good opportunity to get in it because of a recent downgrade from JPMorgan.

APD has already gone from $80 to $100 and now it's time to take it to $120 and beyond, Cramer said.

Stick With Celgene

After the 49th Annual American Society of Hematology conference over the weekend, Celgene (CELG Quote) recently dropped 11 points over two trading days. To make sense of this and talk about Revlimid and its rival drug Velcade, Cramer welcomed the company's COO Bob Hugin to the show.

Celgene's multiple myeloma drug Revlimid, Hugin said, has "unprecedented survival rates" and the longest duration of response. He said the future of the drug is "very bright."

Hugin also called Millennium's (MLNM Quote) multiple myeloma drug Velcade a good drug. However, he said the data for Revlimid is "compelling" and "will speak for itself over time."